Logo image of AGFB.BR

AGFA-GEVAERT NV (AGFB.BR) Stock Fundamental Analysis

EBR:AGFB - Euronext Brussels - BE0003755692 - Common Stock - Currency: EUR

0.893  +0.03 (+3.24%)

Fundamental Rating

2

AGFB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 12 industry peers in the Health Care Technology industry. AGFB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AGFB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AGFB has reported negative net income.
In the past year AGFB has reported a negative cash flow from operations.
In the past 5 years AGFB reported 4 times negative net income.
AGFB had negative operating cash flow in 4 of the past 5 years.
AGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFAGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

1.2 Ratios

AGFB has a Return On Assets of -2.61%. This is in the lower half of the industry: AGFB underperforms 72.73% of its industry peers.
With a Return On Equity value of -9.76%, AGFB is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
AGFB has a Return On Invested Capital of 0.29%. This is in the lower half of the industry: AGFB underperforms 72.73% of its industry peers.
Industry RankSector Rank
ROA -2.61%
ROE -9.76%
ROIC 0.29%
ROA(3y)-6.95%
ROA(5y)0.93%
ROE(3y)-23.67%
ROE(5y)-5.43%
ROIC(3y)N/A
ROIC(5y)N/A
AGFB.BR Yearly ROA, ROE, ROICAGFB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 100

1.3 Margins

AGFB has a worse Operating Margin (0.35%) than 72.73% of its industry peers.
In the last couple of years the Operating Margin of AGFB has declined.
Looking at the Gross Margin, with a value of 31.53%, AGFB is doing worse than 81.82% of the companies in the same industry.
AGFB's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.35%
PM (TTM) N/A
GM 31.53%
OM growth 3Y-17.71%
OM growth 5Y-24.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5Y-0.57%
AGFB.BR Yearly Profit, Operating, Gross MarginsAGFB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AGFB is destroying value.
AGFB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, AGFB has less shares outstanding
AGFB has a worse debt/assets ratio than last year.
AGFB.BR Yearly Shares OutstandingAGFB.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
AGFB.BR Yearly Total Debt VS Total AssetsAGFB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

AGFB has an Altman-Z score of 2.16. This is not the best score and indicates that AGFB is in the grey zone with still only limited risk for bankruptcy at the moment.
AGFB has a Altman-Z score of 2.16. This is comparable to the rest of the industry: AGFB outperforms 54.55% of its industry peers.
A Debt/Equity ratio of 0.40 indicates that AGFB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.40, AGFB perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z 2.16
ROIC/WACC0.03
WACC9.42%
AGFB.BR Yearly LT Debt VS Equity VS FCFAGFB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

AGFB has a Current Ratio of 2.14. This indicates that AGFB is financially healthy and has no problem in meeting its short term obligations.
AGFB has a Current ratio (2.14) which is in line with its industry peers.
A Quick Ratio of 1.24 indicates that AGFB should not have too much problems paying its short term obligations.
AGFB has a Quick ratio (1.24) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 1.24
AGFB.BR Yearly Current Assets VS Current LiabilitesAGFB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

3

3. Growth

3.1 Past

AGFB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.23%, which is quite impressive.
The Revenue for AGFB has decreased by -25.77% in the past year. This is quite bad
Measured over the past years, AGFB shows a very negative growth in Revenue. The Revenue has been decreasing by -12.10% on average per year.
EPS 1Y (TTM)54.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-25.77%
Revenue growth 3Y-12.37%
Revenue growth 5Y-12.1%
Sales Q2Q%-0.35%

3.2 Future

The Earnings Per Share is expected to grow by 29.13% on average over the next years. This is a very strong growth
AGFB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.72% yearly.
EPS Next Y77.05%
EPS Next 2Y40.06%
EPS Next 3Y29.13%
EPS Next 5YN/A
Revenue Next Year1.04%
Revenue Next 2Y2.35%
Revenue Next 3Y2.72%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AGFB.BR Yearly Revenue VS EstimatesAGFB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B 2.5B
AGFB.BR Yearly EPS VS EstimatesAGFB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AGFB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGFB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGFB.BR Price Earnings VS Forward Price EarningsAGFB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AGFB indicates a rather cheap valuation: AGFB is cheaper than 81.82% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 4.96
AGFB.BR Per share dataAGFB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

AGFB's earnings are expected to grow with 29.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.06%
EPS Next 3Y29.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGFB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGFA-GEVAERT NV

EBR:AGFB (2/4/2025, 7:00:00 PM)

0.893

+0.03 (+3.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-14 2024-11-14
Earnings (Next)N/A N/A
Inst Owners55.01%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap138.25M
Analysts74
Price Target1.2 (34.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)22.97%
Min EPS beat(2)-96.08%
Max EPS beat(2)142.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.02%
Min Revenue beat(2)-11.52%
Max Revenue beat(2)-4.53%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-23.53%
EPS NY rev (3m)-23.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.36
P/tB 1.01
EV/EBITDA 4.96
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS7.29
BVpS2.45
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.61%
ROE -9.76%
ROCE 0.39%
ROIC 0.29%
ROICexc 0.31%
ROICexgc 0.41%
OM 0.35%
PM (TTM) N/A
GM 31.53%
FCFM N/A
ROA(3y)-6.95%
ROA(5y)0.93%
ROE(3y)-23.67%
ROE(5y)-5.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-23.56%
ROICexcg growth 5Y-30.85%
ROICexc growth 3Y-23.57%
ROICexc growth 5Y-27.42%
OM growth 3Y-17.71%
OM growth 5Y-24.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5Y-0.57%
F-Score4
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA 3.26
Cap/Depr 95.35%
Cap/Sales 3.63%
Interest Coverage 0.25
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.14
Quick Ratio 1.24
Altman-Z 2.16
F-Score4
WACC9.42%
ROIC/WACC0.03
Cap/Depr(3y)56.62%
Cap/Depr(5y)51.62%
Cap/Sales(3y)2.44%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y77.05%
EPS Next 2Y40.06%
EPS Next 3Y29.13%
EPS Next 5YN/A
Revenue 1Y (TTM)-25.77%
Revenue growth 3Y-12.37%
Revenue growth 5Y-12.1%
Sales Q2Q%-0.35%
Revenue Next Year1.04%
Revenue Next 2Y2.35%
Revenue Next 3Y2.72%
Revenue Next 5YN/A
EBIT growth 1Y102.33%
EBIT growth 3Y-27.89%
EBIT growth 5Y-34.02%
EBIT Next Year241.58%
EBIT Next 3Y70.84%
EBIT Next 5YN/A
FCF growth 1Y61.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.7%
OCF growth 3YN/A
OCF growth 5YN/A